Lessons Unlearned: The Barriers to Lyme Borreliosis Vaccination and the Risk of Repeating History.
Level 5 - mechanism / opinion, no new human data
Narrative review and historical commentary with no primary human data or systematic review methodology.
PubMed 42646715 · doi:10.3390/vaccines14080698
What was done
The authors conducted a narrative and historical review evaluating the commercial and regulatory withdrawal of LYMErix (licensed in 1998, withdrawn in 2002) and examined the evidence underlying its safety controversies. They contextualized these historical challenges in relation to the new second-generation outer surface protein A vaccine candidate, VLA15 (PF-07307405), which completed Phase 3 trials in March 2026 and moved toward regulatory submission.
What was found
The abstract reports epidemiological context indicating approximately 476,000 Lyme borreliosis diagnoses annually in the United States and over 130,000 reported cases across Europe, both considered substantial underestimates. The paper reports that LYMErix was withdrawn four years post-licensure due to eroded public confidence and lack of supportive endorsement rather than evidence of vaccine failure, leaving the field without a licensed vaccine for 24 years. Specific quantitative clinical trial or safety signal metrics are not reported in the abstract.
Why it matters
As a new Lyme disease vaccine nears potential regulatory approval, understanding how past safety controversies and risk-communication failures unfolded is essential to structuring effective post-marketing surveillance and sustaining public confidence in vector-borne disease immunization.
Limits
The publication is a narrative perspective and policy analysis rather than a systematic review or empirical clinical study. The abstract presents no new primary trial data, quantitative risk-benefit calculations, or meta-analytic safety figures.
Cited by
- context The human Lyme disease vaccine was withdrawn from the market following controversy associated with Andrew Wakefield's fraudulent claims linking vaccines to autism.